Neuron23 doses first subject in Phase II trial of NEU-411 for Parkinson’s

Neuron23 doses first subject in Phase II trial of NEU-411 for Parkinson’s

Publication date: Jun 26, 2025

To facilitate subject referrals and identify potential participants, Neuron23 has partnered with Sano Genetics. Give your business an edge with our leading industry insights. Dont let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

Concepts Keywords
Genetics Genetics
Parkinsons Identify
Pharmacodynamics Lrrk2
Smartphone Neu
Weeks Neuron23
Parkinsons
Participants
Partnered
Pd
Phase
Placebo
Potential
Referrals
Subject
Trial

Semantics

Type Source Name
drug DRUGBANK L-Leucine
disease MESH tremor
disease MESH Movement Disorder
drug DRUGBANK Spinosad

Original Article

(Visited 3 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *